Mpox

• CLINICAL_TRIALS trial_result · 2026-04-29
  Clinical Trial Update: Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC [Phase 3]

  Phase 3 infant safety and immunogenicity trial of MVA-BN in the Democratic Republic of Congo is active not recruiting for mpox vaccination i…

• CLINICAL_TRIALS research · 2026-03-30
  Clinical Trial Update: Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo [Phase 4]

  A Phase 4 clinical study in Kinshasa, DRC will monitor the immunological response after Mpox vaccination; the trial is not yet recruiting.

• EMA guidance · 2026-03-27
  EMA recommends restricting use of Tecovirimat SIGA

  EMA recommends restricting the use of Tecovirimat SIGA because it was not effective for treating mpox in randomized clinical trials.

• CLINICAL_TRIALS trial_result · 2026-02-10
  Clinical Trial Update: Study of Tecovirimat for Human Mpox Virus [Phase 3]

  Phase 3 study of tecovirimat for mpox has been terminated; results have been posted (2026-02-10).

• CLINICAL_TRIALS trial_result · 2025-07-16
  Clinical Trial Update: A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age [Phase 1, Phase 2]

  The study reports the completion of a Phase 1/2 trial evaluating the safety, tolerability, and immune response of multiple doses of the inve…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2024-06-06
  Clinical Trial Update: Break-through Infection Following Mpox vaccinatIon

  A completed clinical trial update reports a breakthrough mpox infection occurring after mpox vaccination.